VOYAGEUR PHARMACEUTICALS LTD

Voyageur Pharmaceuticals: Calgary‑based mining firm boosting lithium and barium sulfate output, positioning for growth in EV batteries and oil‑field markets.

Voyageur Pharmaceuticals leads in lithium mining and barium sulfate production, driving growth in battery tech and oil‑field markets despite market volatility.

Voyageur Pharmaceuticals, a TSX Venture mining firm, is expanding lithium exploration and barium sulfate production across Canada & the U.S., poised to meet EV and renewable energy demand.

Voyageur Pharmaceuticals’ declining stock, negative P/E, and lithium‑focused strategy expose key challenges for investors seeking insights into its future viability.

Voyageur Pharmaceuticals partners with Bayer, securing up to $2.35 M in milestone‑based funding and exclusivity to develop U.S. iodine contrast media, aiming to cut supply‑chain dependence and boost medical imaging supplies.

Voyageur Pharmaceuticals’ stock hits a new low after a volatile 2025; negative P/E and high P/B signal investor caution and the need for strategic change.

Voyageur Pharmaceuticals’ volatile TSX stock reflects its lithium & barium sulfate focus—investors eye future growth amid current financial challenges.